These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31448852)

  • 1. Opportunities for improving use of evidence-based therapy in patients with type 2 diabetes and cardiovascular disease.
    Gao Y; Peterson E; Pagidipati N
    Clin Cardiol; 2019 Nov; 42(11):1063-1070. PubMed ID: 31448852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes.
    Dey AK; Groenendyk J; Mehta NN; Gourgari E
    Clin Cardiol; 2019 Mar; 42(3):406-412. PubMed ID: 30635924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review.
    Newman JD; Vani AK; Aleman JO; Weintraub HS; Berger JS; Schwartzbard AZ
    J Am Coll Cardiol; 2018 Oct; 72(15):1856-1869. PubMed ID: 30286929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
    Yu J; Shah BM; Ip EJ; Chan J
    J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration.
    Chang LS; Vaduganathan M; Plutzky J; Aroda VR
    Curr Diab Rep; 2019 Dec; 19(12):157. PubMed ID: 31802265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of diabetes and associated cardiometabolic risk factors on members: strategies for optimizing outcomes.
    Hoerger TJ; Ahmann AJ
    J Manag Care Pharm; 2008 Feb; 14(1 Suppl C):S2-14; quiz 15-6. PubMed ID: 18240890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?
    Lovre D; Htun W; Carrion C; Fonseca VA
    Curr Diab Rep; 2016 Oct; 16(10):94. PubMed ID: 27541296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ
    Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.
    Tanaka A; Node K
    Cardiovasc Diabetol; 2018 Jun; 17(1):85. PubMed ID: 29895290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Antidiabetic Agents and Cardiovascular Outcomes.
    Pareek M; Bhatt DL
    Curr Probl Cardiol; 2018 Mar; 43(3):111-126. PubMed ID: 28844525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Diabetes Drugs and the Cardiovascular Specialist.
    Sattar N; Petrie MC; Zinman B; Januzzi JL
    J Am Coll Cardiol; 2017 May; 69(21):2646-2656. PubMed ID: 28545639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic implications with newer agents to reduce cardiovascular risk in diabetes.
    McAdam-Marx C
    Am J Manag Care; 2018 Aug; 24(13 Suppl):S279-S285. PubMed ID: 30160395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review on cardiovascular effects of newer hypoglycaemic medications.
    Cutshall BT; Twilla JD; Olinger AS; Oliphant CS
    Ann Med; 2017 Nov; 49(7):603-612. PubMed ID: 28540743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits.
    Gao Y; Peterson E; Pagidipati N
    Am Heart J; 2020 Jun; 224():47-53. PubMed ID: 32304879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.
    Sharma A; Verma S
    Can J Diabetes; 2020 Feb; 44(1):93-102. PubMed ID: 31882322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
    Woo V; Connelly K; Lin P; McFarlane P
    Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.